The Experts below are selected from a list of 525 Experts worldwide ranked by ideXlab platform
Christoph Reiners - One of the best experts on this subject based on the ideXlab platform.
-
thyroid hormone withdrawal in patients with differentiated thyroid carcinoma a one hundred thirty patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to Recombinant Thyrotropin administration
Thyroid, 2005Co-Authors: Markus Luster, Ralph Felbinger, Markus Dietlein, Christoph ReinersAbstract:The study objective was to elucidate clinical, quality-of-life, and pharmacoeconomic effects of hypothyroidism secondary to thyroid hormone withdrawal (withdrawal) in athyroid patients with differentiated thyroid cancer (DTC). We also intended to compare societal costs of withdrawal and Recombinant human thyroid-stimulating hormone administration (rhTSH) in this population. We mailed a 13-item pilot survey to patients with DTC who had undergone withdrawal before diagnostic whole-body scan (dxWBS). Using survey results and actual and estimated cost data, we retrospectively constructed a societal cost model comparing withdrawal versus rhTSH and performed a sensitivity analysis by increasing the conservatism of 8 assumptions about withdrawal costs. One hundred thirty (55%) of 236 patients answered the questionnaire. Among respondents, 92% had symptomatic and 85% multisymptomatic hypothyroidism. Almost half sought medical attention for hypothyroid complaints. Approximately one third drove motor vehicles while...
-
thyroid hormone withdrawal in patients with differentiated thyroid carcinoma a one hundred thirty patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to Recombinant Thyrotropin administration
Thyroid, 2005Co-Authors: Markus Luster, Ralph Felbinger, Markus Dietlein, Christoph ReinersAbstract:The study objective was to elucidate clinical, quality-of-life, and pharmacoeconomic effects of hypothyroidism secondary to thyroid hormone withdrawal (withdrawal) in athyroid patients with differentiated thyroid cancer (DTC). We also intended to compare societal costs of withdrawal and Recombinant human thyroid-stimulating hormone administration (rhTSH) in this population. We mailed a 13-item pilot survey to patients with DTC who had undergone withdrawal before diagnostic whole-body scan (dxWBS). Using survey results and actual and estimated cost data, we retrospectively constructed a societal cost model comparing withdrawal versus rhTSH and performed a sensitivity analysis by increasing the conservatism of 8 assumptions about withdrawal costs. One hundred thirty (55%) of 236 patients answered the questionnaire. Among respondents, 92% had symptomatic and 85% multisymptomatic hypothyroidism. Almost half sought medical attention for hypothyroid complaints. Approximately one third drove motor vehicles while hypothyroid. Median absence from salaried work was 11 days per withdrawal. In the pharmacoeconomic model, societal costs per dxWBS were approximately 326 euro (25%) greater for withdrawal than for rhTSH. In the sensitivity analysis, societal costs of rhTSH exceeded those of withdrawal by approximately 307 euro (30%). In conclusion, hypothyroidism secondary to withdrawal causes important morbidity, safety risks, and productivity impairment. rhTSH avoids these drawbacks at roughly equivalent societal cost to that of withdrawal.
Markus Luster - One of the best experts on this subject based on the ideXlab platform.
-
Recombinant Thyrotropin use in children and adolescents with differentiated thyroid cancer a multicenter retrospective study
The Journal of Clinical Endocrinology and Metabolism, 2009Co-Authors: Markus Luster, Daria Handkiewiczjunak, Armando Grossi, Margaret Zacharin, David Taieb, Ofelia Cruz, Anne Hitzel, Juan Antonio Vallejo Casas, Uwe Mader, Massimo E DottoriniAbstract:Context: Although Recombinant human TSH (rhTSH) is widely used in differentiated thyroid cancer (DTC) to aid diagnostic follow-up procedures and radioiodine thyroid remnant ablation, almost all clinical investigation was in adults. Objective: The aim of this study was to characterize rhTSH clinical safety and peak TSH response in DTC patients 18 yr old or younger. Design and Setting: We conducted a retrospective study involving 23 tertiary referral centers in 12 European, Asian, and Oceanian countries. Patients: One hundred DTC patients (69% female, 31% male, 84% papillary, 61% N1, 18% M1) ages 4.9–18 yr at first rhTSH administration were studied. Interventions: A total of 181 rhTSH courses were administered (range, one to eight per patient; 42% of patients received two or more courses), 92% using the approved adult regimen (one 0.9 mg im injection daily on two consecutive days), 34% including thyroid hormone withdrawal for less than 7 d (“mini-THW”). Main Outcome Measures: Clinical adverse event (AE) inc...
-
thyroid hormone withdrawal in patients with differentiated thyroid carcinoma a one hundred thirty patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to Recombinant Thyrotropin administration
Thyroid, 2005Co-Authors: Markus Luster, Ralph Felbinger, Markus Dietlein, Christoph ReinersAbstract:The study objective was to elucidate clinical, quality-of-life, and pharmacoeconomic effects of hypothyroidism secondary to thyroid hormone withdrawal (withdrawal) in athyroid patients with differentiated thyroid cancer (DTC). We also intended to compare societal costs of withdrawal and Recombinant human thyroid-stimulating hormone administration (rhTSH) in this population. We mailed a 13-item pilot survey to patients with DTC who had undergone withdrawal before diagnostic whole-body scan (dxWBS). Using survey results and actual and estimated cost data, we retrospectively constructed a societal cost model comparing withdrawal versus rhTSH and performed a sensitivity analysis by increasing the conservatism of 8 assumptions about withdrawal costs. One hundred thirty (55%) of 236 patients answered the questionnaire. Among respondents, 92% had symptomatic and 85% multisymptomatic hypothyroidism. Almost half sought medical attention for hypothyroid complaints. Approximately one third drove motor vehicles while...
-
thyroid hormone withdrawal in patients with differentiated thyroid carcinoma a one hundred thirty patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to Recombinant Thyrotropin administration
Thyroid, 2005Co-Authors: Markus Luster, Ralph Felbinger, Markus Dietlein, Christoph ReinersAbstract:The study objective was to elucidate clinical, quality-of-life, and pharmacoeconomic effects of hypothyroidism secondary to thyroid hormone withdrawal (withdrawal) in athyroid patients with differentiated thyroid cancer (DTC). We also intended to compare societal costs of withdrawal and Recombinant human thyroid-stimulating hormone administration (rhTSH) in this population. We mailed a 13-item pilot survey to patients with DTC who had undergone withdrawal before diagnostic whole-body scan (dxWBS). Using survey results and actual and estimated cost data, we retrospectively constructed a societal cost model comparing withdrawal versus rhTSH and performed a sensitivity analysis by increasing the conservatism of 8 assumptions about withdrawal costs. One hundred thirty (55%) of 236 patients answered the questionnaire. Among respondents, 92% had symptomatic and 85% multisymptomatic hypothyroidism. Almost half sought medical attention for hypothyroid complaints. Approximately one third drove motor vehicles while hypothyroid. Median absence from salaried work was 11 days per withdrawal. In the pharmacoeconomic model, societal costs per dxWBS were approximately 326 euro (25%) greater for withdrawal than for rhTSH. In the sensitivity analysis, societal costs of rhTSH exceeded those of withdrawal by approximately 307 euro (30%). In conclusion, hypothyroidism secondary to withdrawal causes important morbidity, safety risks, and productivity impairment. rhTSH avoids these drawbacks at roughly equivalent societal cost to that of withdrawal.
Ralph Felbinger - One of the best experts on this subject based on the ideXlab platform.
-
thyroid hormone withdrawal in patients with differentiated thyroid carcinoma a one hundred thirty patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to Recombinant Thyrotropin administration
Thyroid, 2005Co-Authors: Markus Luster, Ralph Felbinger, Markus Dietlein, Christoph ReinersAbstract:The study objective was to elucidate clinical, quality-of-life, and pharmacoeconomic effects of hypothyroidism secondary to thyroid hormone withdrawal (withdrawal) in athyroid patients with differentiated thyroid cancer (DTC). We also intended to compare societal costs of withdrawal and Recombinant human thyroid-stimulating hormone administration (rhTSH) in this population. We mailed a 13-item pilot survey to patients with DTC who had undergone withdrawal before diagnostic whole-body scan (dxWBS). Using survey results and actual and estimated cost data, we retrospectively constructed a societal cost model comparing withdrawal versus rhTSH and performed a sensitivity analysis by increasing the conservatism of 8 assumptions about withdrawal costs. One hundred thirty (55%) of 236 patients answered the questionnaire. Among respondents, 92% had symptomatic and 85% multisymptomatic hypothyroidism. Almost half sought medical attention for hypothyroid complaints. Approximately one third drove motor vehicles while...
-
thyroid hormone withdrawal in patients with differentiated thyroid carcinoma a one hundred thirty patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to Recombinant Thyrotropin administration
Thyroid, 2005Co-Authors: Markus Luster, Ralph Felbinger, Markus Dietlein, Christoph ReinersAbstract:The study objective was to elucidate clinical, quality-of-life, and pharmacoeconomic effects of hypothyroidism secondary to thyroid hormone withdrawal (withdrawal) in athyroid patients with differentiated thyroid cancer (DTC). We also intended to compare societal costs of withdrawal and Recombinant human thyroid-stimulating hormone administration (rhTSH) in this population. We mailed a 13-item pilot survey to patients with DTC who had undergone withdrawal before diagnostic whole-body scan (dxWBS). Using survey results and actual and estimated cost data, we retrospectively constructed a societal cost model comparing withdrawal versus rhTSH and performed a sensitivity analysis by increasing the conservatism of 8 assumptions about withdrawal costs. One hundred thirty (55%) of 236 patients answered the questionnaire. Among respondents, 92% had symptomatic and 85% multisymptomatic hypothyroidism. Almost half sought medical attention for hypothyroid complaints. Approximately one third drove motor vehicles while hypothyroid. Median absence from salaried work was 11 days per withdrawal. In the pharmacoeconomic model, societal costs per dxWBS were approximately 326 euro (25%) greater for withdrawal than for rhTSH. In the sensitivity analysis, societal costs of rhTSH exceeded those of withdrawal by approximately 307 euro (30%). In conclusion, hypothyroidism secondary to withdrawal causes important morbidity, safety risks, and productivity impairment. rhTSH avoids these drawbacks at roughly equivalent societal cost to that of withdrawal.
Markus Dietlein - One of the best experts on this subject based on the ideXlab platform.
-
thyroid hormone withdrawal in patients with differentiated thyroid carcinoma a one hundred thirty patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to Recombinant Thyrotropin administration
Thyroid, 2005Co-Authors: Markus Luster, Ralph Felbinger, Markus Dietlein, Christoph ReinersAbstract:The study objective was to elucidate clinical, quality-of-life, and pharmacoeconomic effects of hypothyroidism secondary to thyroid hormone withdrawal (withdrawal) in athyroid patients with differentiated thyroid cancer (DTC). We also intended to compare societal costs of withdrawal and Recombinant human thyroid-stimulating hormone administration (rhTSH) in this population. We mailed a 13-item pilot survey to patients with DTC who had undergone withdrawal before diagnostic whole-body scan (dxWBS). Using survey results and actual and estimated cost data, we retrospectively constructed a societal cost model comparing withdrawal versus rhTSH and performed a sensitivity analysis by increasing the conservatism of 8 assumptions about withdrawal costs. One hundred thirty (55%) of 236 patients answered the questionnaire. Among respondents, 92% had symptomatic and 85% multisymptomatic hypothyroidism. Almost half sought medical attention for hypothyroid complaints. Approximately one third drove motor vehicles while...
-
thyroid hormone withdrawal in patients with differentiated thyroid carcinoma a one hundred thirty patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to Recombinant Thyrotropin administration
Thyroid, 2005Co-Authors: Markus Luster, Ralph Felbinger, Markus Dietlein, Christoph ReinersAbstract:The study objective was to elucidate clinical, quality-of-life, and pharmacoeconomic effects of hypothyroidism secondary to thyroid hormone withdrawal (withdrawal) in athyroid patients with differentiated thyroid cancer (DTC). We also intended to compare societal costs of withdrawal and Recombinant human thyroid-stimulating hormone administration (rhTSH) in this population. We mailed a 13-item pilot survey to patients with DTC who had undergone withdrawal before diagnostic whole-body scan (dxWBS). Using survey results and actual and estimated cost data, we retrospectively constructed a societal cost model comparing withdrawal versus rhTSH and performed a sensitivity analysis by increasing the conservatism of 8 assumptions about withdrawal costs. One hundred thirty (55%) of 236 patients answered the questionnaire. Among respondents, 92% had symptomatic and 85% multisymptomatic hypothyroidism. Almost half sought medical attention for hypothyroid complaints. Approximately one third drove motor vehicles while hypothyroid. Median absence from salaried work was 11 days per withdrawal. In the pharmacoeconomic model, societal costs per dxWBS were approximately 326 euro (25%) greater for withdrawal than for rhTSH. In the sensitivity analysis, societal costs of rhTSH exceeded those of withdrawal by approximately 307 euro (30%). In conclusion, hypothyroidism secondary to withdrawal causes important morbidity, safety risks, and productivity impairment. rhTSH avoids these drawbacks at roughly equivalent societal cost to that of withdrawal.
Steven I Sherman - One of the best experts on this subject based on the ideXlab platform.
-
the role of Recombinant human Thyrotropin for diagnostic monitoring of patients with differentiated thyroid cancer
Endocrine Practice, 2013Co-Authors: Steven I ShermanAbstract:ABSTRACT Objective To describe the evolving role of Recombinant human Thyrotropin in the diagnostic evaluation of patients treated for differentiated thyroid carcinoma. Methods A systematic review was performed of published English language articles appearing in PubMed using terms “Recombinant Thyrotropin” and “thyroid cancer”. The author selected articles for inclusion based upon potential for clinical impact of the reported findings. Results The addition of Recombinant human Thyrotropin to diagnostic testing replaced the requirement for thyroid hormone withdrawal and symptomatic hypothyroidism that had been necessary to generate sufficient endogenous Thyrotropin for radioiodine scanning and thyroglobulin testing. The high negative predictive value of stimulated thyroglobulin testing removed the need for serial radioiodine scanning for many patients, but repeated stimulated testing rarely appeared to add significantly. The development of highly sensitive second generation thyroglobulin assays may replace the need for stimulated testing in a subset of patients. Conclusion Recombinant human Thyrotropin-stimulated testing continues to be a valuable component of follow-up testing in the first year after initial treatment of differentiated thyroid cancer. (Endocr Pract. 2013;19: 157-161)
-
assessment of the incremental value of Recombinant Thyrotropin stimulation before 2 18f fluoro 2 deoxy d glucose positron emission tomography computed tomography imaging to localize residual differentiated thyroid cancer
The Journal of Clinical Endocrinology and Metabolism, 2009Co-Authors: Sophie Leboulleux, Pamela R Schroeder, Naifa L Busaidy, Anne Auperin, C Corone, Heather A Jacene, Marjorie Ewertz, C Bournaud, Richard L Wahl, Steven I ShermanAbstract:Purpose: The purpose of the study was to assess prospectively the impact of Recombinant human TSH (rhTSH) administration on positron emission tomography (PET)/computed tomography (CT) imaging in differentiated thyroid cancer patients who, after primary treatment, had a suppressed or stimulated serum thyroglobulin greater than 10 ng/ml and no radioactive iodine uptake consistent with thyroid cancer on a whole body scan. Patients and Methods: PET/CT was performed before (basal PET) and 24–48 h after rhTSH administration (rhTSH-PET) in 63 patients (52 papillary and 11 follicular thyroid cancers). Images were blindly analyzed by two readers. The proposed treatment plan was prospectively assessed before basal PET, after basal PET, and again after rhTSH-PET. Results: A total of 108 lesions were detected in 48 organs in 30 patients. rhTSH-PET was significantly more sensitive than basal PET for the detection of lesions (95 vs. 81%; P = 0.001) and tended to be more sensitive for the detection of involved organs (9...